Avelumab and Merkel Cell Carcinoma: Clinical Evidence Review on Causation

Legacy of General Health and Science Information

The legacy of general health and science information has long emphasized the importance of understanding environmental and pharmaceutical exposures in relation to disease outcomes. Within this broad context, public health surveillance and clinical evidence review have historically focused on infectious agents, lifestyle factors, and common chemical hazards. As scientific inquiry has matured, attention has increasingly turned toward specific therapeutic agents and their potential unintended consequences. One such area of growing interest involves the immunotherapeutic agent avelumab, which has been approved for the treatment of Merkel cell carcinoma. This shift from general health education to targeted pharmacovigilance reflects a natural progression in evidence-based medicine. In occupational settings, workers in healthcare, pharmaceutical manufacturing, or research laboratories may encounter avelumab through preparation, administration, or accidental exposure. The transition from a general health framework to an occupational exposure concern requires careful consideration of how clinical evidence on avelumab and Merkel cell carcinoma causation informs risk assessment for these workers. By examining the available clinical data, occupational health professionals can better understand potential exposure scenarios and implement appropriate protective measures. This pivot underscores the need for integrating clinical findings into workplace safety protocols, ensuring that the legacy of health information continues to serve both clinical and occupational populations effectively.

Clinical Evidence on Avelumab and Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Despite these advances, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Clinical presentation of MCC typically involves a rapidly growing, painless, firm, red or purple nodule on sun-exposed skin, often in older or immunocompromised individuals. Diagnosis is confirmed by histopathology and immunohistochemistry, showing neuroendocrine markers such as cytokeratin 20 and chromogranin A. Avelumab functions as an immune checkpoint inhibitor by blocking PD-L1, thereby enhancing T-cell activity against tumor cells (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, this mechanism can lead to overactivation of the immune system, resulting in immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). Reported irAEs include hypercalcaemia due to reactivation of sarcoidosis, as described in a case of a patient with metastatic MCC on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). In that case, hypercalcaemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other immune-related adverse events are common with checkpoint inhibitors, though specific rates for avelumab in MCC are not detailed in the provided evidence.

Mechanistic Pathways and Risk Considerations

The primary mechanistic link between avelumab and MCC is therapeutic: avelumab is designed to treat MCC by inhibiting PD-L1, thereby restoring anti-tumor immune responses (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, the evidence also describes a scenario where avelumab may be associated with disease progression or lack of response. For patients refractory to avelumab, alternative treatments such as ipilimumab plus nivolumab have been studied (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). In a multicenter study, three out of five avelumab-refractory patients responded to combined ipilimumab/nivolumab according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another study reported response rates to PD-1/PD-L1 inhibition in MCC of up to 62%, but also noted that about 50% of patients progress on therapy (https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). These data suggest that while avelumab can be effective, resistance or refractoriness is a significant clinical issue, and mechanistic pathways for resistance are not fully elucidated in the provided evidence. Regarding risk considerations, the evidence indicates that avelumab is approved for metastatic MCC independent of line of treatment, and its use is associated with immune-related adverse events (https://pubmed.ncbi.nlm.nih.gov/29799096/; https://pubmed.ncbi.nlm.nih.gov/31543781/). However, the provided snippets do not include specific warnings about the risk of avelumab causing or exacerbating MCC. Rather, avelumab is a treatment for MCC, and the risk of progression or lack of response is documented. For example, about 50% of patients with advanced MCC progress on immune checkpoint inhibitors, including avelumab (https://pubmed.ncbi.nlm.nih.gov/35877101/). This suggests that warnings regarding potential treatment failure and the need for alternative therapies are relevant. For affected patients, the primary causation question is whether avelumab can cause MCC. The evidence does not support a causal link between avelumab and the development of MCC. Instead, avelumab is used to treat MCC. However, the evidence does document that avelumab can cause immune-related adverse events, such as hypercalcaemia from sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who experience progression while on avelumab, the drug may be considered a contributing factor to lack of disease control, but not a cause of the cancer itself. The evidence does not provide specific timelines for harm from avelumab in MCC. In the case of hypercalcaemia due to sarcoidosis, the event occurred during treatment, and resolution was achieved with corticosteroids while continuing avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). For treatment-refractory disease, the timeline of progression is not specified in the provided snippets, but clinical trials typically assess response at intervals (e.g., every 6-8 weeks). The JAVELIN Merkel 200 trial reported objective responses in about one-third of patients, implying that non-response or progression may be evident within weeks to months of starting therapy (https://pubmed.ncbi.nlm.nih.gov/29799096/). In conclusion, avelumab is an effective treatment for metastatic MCC, with a mechanism of action that can lead to immune-related adverse events. The evidence does not indicate that avelumab causes MCC; rather, it is a therapeutic agent. Risks include treatment failure in about 50% of patients and irAEs such as hypercalcaemia. Warnings should address these risks, and patients should be monitored for progression and adverse events. Causation considerations focus on treatment outcomes rather than drug-induced carcinogenesis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can avelumab cause Merkel cell carcinoma?

No, the clinical evidence does not support a causal link between avelumab and the development of Merkel cell carcinoma. Avelumab is a therapeutic agent used to treat metastatic Merkel cell carcinoma by inhibiting PD-L1 and enhancing anti-tumor immune responses (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What are the risks associated with avelumab treatment for Merkel cell carcinoma?

Risks include treatment failure in about 50% of patients with advanced Merkel cell carcinoma who progress on immune checkpoint inhibitors, including avelumab (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, avelumab can cause immune-related adverse events such as hypercalcaemia due to sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.